(Q42234559)

19 October 2017

title

Pertussis vaccines: position paper of Indian Academy of Pediatrics (IAP). (English)

1 reference

19 October 2017

0 references

1

Vipin M Vashishtha

1 reference

19 October 2017

C P Bansal

2

1 reference

19 October 2017

Sailesh G Gupta

series ordinal

3

1 reference

19 October 2017

publication date

1 November 2013

1 reference

19 October 2017

1 reference

19 October 2017

volume

50

1 reference

19 October 2017

issue

11

1 reference

19 October 2017

page(s)

1001-1009

1 reference

California pertussis epidemic, 2010.

19 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Pertussis: a review of disease epidemiology worldwide and in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Re-emergence of pertussis: what are the solutions?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Pertussis resurgence among vaccinated children in Khairpur, Sindh, Pakistan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Epidemic pertussis in 2012--the resurgence of a vaccine-preventable disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Antibody response patterns to Bordetella pertussis antigens in vaccinated (primed) and unvaccinated (unprimed) young children with pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Sustained efficacy during the first 6 years of life of 3-component acellular pertussis vaccines administered in infancy: the Italian experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Immunity to Bordetella pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Waning protection after fifth dose of acellular pertussis vaccine in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Duration of immunity against pertussis after natural infection or vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Hospital-based active surveillance of childhood pertussis in Austria from 1996 to 2003: estimates of incidence and vaccine effectiveness of whole-cell and acellular vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Effectiveness of adolescent and adult tetanus, reduced-dose diphtheria, and acellular pertussis vaccine against pertussis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared to recipients of acellular pertussis vaccines in a large US cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Priming with whole-cell versus acellular pertussis vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Systematic review of the effects of pertussis vaccines in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Adolescent vaccination-coverage levels in the United States: 2006-2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Impact of maternal postpartum tetanus and diphtheria toxoids and acellular pertussis immunization on infant pertussis infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Prospects for prevention of childhood infections by maternal immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Th2-polarisation of cellular immune memory to neonatal pertussis vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Risk factors for acellular and whole-cell pertussis vaccine failure in Senegalese children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

Number and Order of Whole Cell Pertussis Vaccines in Infancy and Disease Protection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS13312-013-0274-Y

10.1007/S13312-013-0274-Y

21 January 2018

Identifiers

DOI

1 reference

19 October 2017

1 reference